Work

Herpes simplex virus type-2 assay specificity and male circumcision to reduce herpes simplex virus type-2 acquisition

Year: 2012

Type: letter

Abstract: Three male circumcision trials which enrolled over 10 000 men of different ages, settings (urban vs. rural), and countries (Uganda, Kenya, and South Africa), and which utilized different surgical techniques were consistent in showing a 51–60% reduction in HIV incidence [1–5], and all three trials reported that male circumcision decreased high-risk human papillomavirus (HR-HPV) prevalence by 32–35% [6–8]. In addition, both the Ugandan and Kenyan trials showed that male circumcision reduced genital ulcer disease by 47–48% [1,9]. As the majority of genital ulcers in both men and women are due to herpes simplex virus type-2 (HSV-2) [10–12], it was hypothesized that male circumcision also reduces HSV-2 acquisition. The Ugandan and South African trials evaluated this hypothesis and reported that male circumcision reduced HSV-2 incidence by 25–34% [8,13]. Interestingly, however, Mehta et al.[9] did not find similar efficacy in the Kenyan trial in Kisumu. All three trials utilized an ELISA manufactured by Kalon Biological (Guildford, UK) to detect incident HSV-2. However, interpretation of this assay to detect HSV-2 seroconversion can be problematic, because the index value to define a positive result may differ from the manufacturer's recommended cutoff based on European and North American populations and HSV-2 viruses [14]. There are multiple reports of high false-positive rates among African samples [14–18]. We and others found that a higher index cutoff value is required for optimal sensitivity and specificity [14,16,19]. When used according to manufacturer's instructions (index cutoff value 1.1), the Kalon ELISA had a sensitivity of 95.1% and a specificity of only 87.6% in Uganda compared to western blot [14], whereas a Kalon index value cutoff of 1.5 resulted in a sensitivity of 91.7% and a specificity of 92.4% [14]. Specificity increased to 97.6% with an index value of 2.5 and 98.4% with an index value of 3.5 [14]. In a validation study among men enrolled in the male circumcision trial in Kisumu, the Kalon ELISA at the recommended manufacturer's cutoff had low sensitivity (92%) and specificity (79%) [20]. In their analysis, Mehta et al.[9] used the manufacturer's cutoff to evaluate the efficacy of male circumcision to reduce HSV-2 incidence, a cutoff which is likely to have reduced specificity and may have biased their results toward the null. Mehta et al.[9] noted that ‘no differences were found between circumcised and uncircumcised men at other cutoff values of 1.5, 2.0, 2.5, 3.0, and 3.5.’ However, to determine whether improved specificity affected male circumcision efficacy estimates in the Ugandan trial, we assessed HSV-2 seroconverters classified by higher Kalon ELISA index values which maximize specificity and reduce potential false positives. For HSV-2 seroconversion rate and person time calculations, it was assumed that HSV-2 infection occurred at the mid-time point between the last negative and first positive serological tests. Time from enrollment was accumulated to the 24-month follow-up visit or the last available sample visit, and HSV-2 seroconversions were estimated per 100 person-years. Incidence rate ratios and 95% confidence intervals were estimated using Poisson regression. As HSV-2 assay specificity increased, male circumcision efficacy to prevent HSV-2 infection increased, though modestly (Table 1). Thus, the previously reported 25–34% reduction in HSV-2 from the Ugandan and South African trials likely represent conservative estimates.Table 1: Herpes simplex virus type-2 incidence among men in the intervention group (circumcised) and control group based on Kalon index value.As Mehta et al. note in the discussion, the lack of an association between male circumcision and reduced incident HSV-2 in the Kenyan trial may be due to poor test performance. The results of the Ugandan and Kenyan trials showing reduced genital ulceration following male circumcision and the results of the Ugandan and South African male circumcision trials showing reduced HSV-2 acquisition appear consistent. The analysis in Table 1 suggests that higher assay specificity further strengthens the observed associations that male circumcision reduces both HSV-2 incidence and genital ulcer disease. Acknowledgements Conflicts of interest There are no conflicts of interest.

Source: AIDS

DOI: 10.1097/qad.0b013e32835aa181

Authors: Aaron A.R. Tobian, Godfrey Kigozi, Maria J. Wawer, David Serwadda, Thomas C. Quinn, Ronald H. Gray